TY - JOUR
T1 - Response to Mazzaschi and Buti
AU - Hopkins, Ashley M.
AU - Sorich, Michael J.
PY - 2022/10
Y1 - 2022/10
N2 - We thank Mazzaschi and Buti for their comments on the article entitled “Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor (PPI) Treatment: Pooled Analysis of Five Randomized Control Trials.”1 We read,with interest, the proposition for future research on the impacts of concomitantly dosed corticosteroids and probiotics on the efficacy of atezolizumab-based regimens in NSCLC, which has merit. However, prestudy, it was determined that the evaluation of subgroups within subgroups (i.e., corticosteroids users within the PPI users, who are randomized atezolizumab) would have limited validity on interaction analysis.
AB - We thank Mazzaschi and Buti for their comments on the article entitled “Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor (PPI) Treatment: Pooled Analysis of Five Randomized Control Trials.”1 We read,with interest, the proposition for future research on the impacts of concomitantly dosed corticosteroids and probiotics on the efficacy of atezolizumab-based regimens in NSCLC, which has merit. However, prestudy, it was determined that the evaluation of subgroups within subgroups (i.e., corticosteroids users within the PPI users, who are randomized atezolizumab) would have limited validity on interaction analysis.
KW - Antibiotics
KW - Atezolizumab
KW - Gut dysbiosis
KW - Non–small cell lung cancer
KW - Proton pump inhibitors
KW - Survival
KW - Corticosteroids
UR - http://www.scopus.com/inward/record.url?scp=85139022336&partnerID=8YFLogxK
UR - http://purl.org/au-research/grants/NHMRC/2008119
U2 - 10.1016/j.jtho.2022.07.1145
DO - 10.1016/j.jtho.2022.07.1145
M3 - Letter
C2 - 36192081
AN - SCOPUS:85139022336
SN - 1556-0864
VL - 17
SP - e90
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 10
ER -
